Showing posts with label Neurology. Show all posts
Showing posts with label Neurology. Show all posts

22 January 2012

Cranial Nerve Diseases Ppts




Cranial  Nerve Diseases
http://webhome.broward.edu/~sfinazzo/student%20Projects/cranial%20nerve%20disorder/Cranial%20Nerve%20Diseases%20PPswee.ppt

Facial Nerve Paralysis
by Vanessa S. Rothholtz, M.D., M.Sc.
http://www.ent.uci.edu/grand%20round%20archives/FacialNerveParalysis%20May%2024,%202007%20V.%20Rothholtz.ppt

Summary of Function of Cranial Nerves
http://www.cerritos.edu/charbut/AP150/lec_otl/150%20Cranial%20nerves.ppt

Cranial Nerves I through XII
http://wc.pima.edu/~ahaber/bio203/cranial%20nerve%20ppt.ppt

Neoplastic & Autoimmune CNS Disorders
http://www.meded.umn.edu/courses_y34/NEUR_7510/documents/Tuite/session7.ppt

Cranial  Nerves-12 Pairs
Olfactory, Optic, Oculomotor, Trochlear, Trigeminal, Abducens, Facial, Vestibulocochlear, Glossopharyngeal, Vagus, Spinal Accessory, Hypoglossal
http://people.musc.edu/~thomaskj/CHP%20Anatomy/Unit%203/Lecture%20005%20-%20cranial%20nerves.ppt

Read more...

14 December 2011

Carpal Tunnel Syndrome (CTS)ppts and publications



Carpal Tunnel  Syndrome (CTS)ppts and publications

Nerve Compression  Syndromes
http://osm-web05.orthop.washington.edu/UserFiles/File/cme/leopold2.ppt

Diagnosis  of Carpal Tunnel
http://www.biol.wwu.edu/lapsansk/349/carpal_tunnel.ppt

Carpal Tunnel  Syndrome
http://www.duke.edu/~ajb11/CTS.ppt

Carpal Tunnel  Syndrome
By: Tino Cantu And Maggie Sanchez
http://www.laredo.edu/science/rviswanath/BIOL2401PPT/Carpal%20Tunnel%20Syndrome.ppt

Carpal Tunnel Syndrome
By NathaëlF Hyppolite  RIII MF
http://www.pitt.edu/~super7/22011-23001/22951.ppt

Carpal Tunnel  Syndrome (CTS)
Rachel M  Schutz
https://pantherfile.uwm.edu/seon/www/CTS.ppt

Carpal  Tunnel Syndrome (CTS)
http://www.medschool.lsuhsc.edu/neurology/students/docs/Module%20CTS.ppt

Avoiding Carpal Tunnel Syndrome
By Kathy Ames
http://facultystaff.vwc.edu/~kames/carpal%20tunnel%20syndrome.ppt

Latest 20 Publications

Read more...

31 August 2011

Autism Spectrum Disorder presentations



Autism Spectrum Disorders
http://www.umaryland.edu/bin/g/d/Autism%20Spectrum%20Disorders%20Presentation.ppt

Treatments for Autism Spectrum Disorders
by Lynda  Maniscalco, M.S. CCC-SLP
http://cied.uark.edu/TreatmentsForASD.pptx

History of Autism Spectrum Disorders
http://uscm.med.sc.edu/autism_project/Module%201%20Lesson%201.pps

Autism Spectrum Disorders (ASD)
http://users.phhp.ufl.edu/jhj/ASD.ppt

Transition and Autism Spectrum Disorders: Myths, musings..
by Dr. Cheryl A. Young, BCABA
http://www.msubillings.edu/summer/SafeSchoolsDocs/Transition-Autism-Myths.ppt

Early Expression of Autism Spectrum Disorders
by Kasia Chawarska, Ph.D. Yale University School of Medicine
http://autism.yale.edu/sites/default/files/Class_4_Chawarska_CLEAR.ppt

Understanding Autism Spectrum Disorders
http://uscm.med.sc.edu/autism_project/Module%201%20Lesson%202.pps

Autism Spectrum Disorders 
By Kirsten Moreland and Kelsey Burns
http://www.d.umn.edu/~thughes/documents/AutismKirKel.ppt

Autism Spectrum Disorders &  Workplace Discrimination
http://cied.uark.edu/ToddVanWierenASD_and_TitleI_WorkplaceDiscrimination.ppt

Nuts and Bolts: Autism Spectrum Disorders
http://www.uwex.edu/ces/flp/conference/documents/Johnson_NutsandBolts.ppt

Nutritional Considerations in Autism Spectrum Disorders
by Anne Roland Lee, MSEd, RD, Columbia University
http://www.hunter.cuny.edu/school-of-education/special-programs-and-centers/regional-autism-center/repository/files/ppt-December-2006-Part-2.ppt

Read more...

01 May 2011

Cerebral Palsy ppt



Hemiplegic Cerebral Palsy

Constraint-Induced Movement Therapy
By Lindsey Nichols-Masaki, Ana Maria Vascan
https://mywebspace.wisc.edu/vascan/web/CD503_CIMTpresentation.ppt

Physical Disabilities Cerebral Palsy
http://www.hhs.csus.edu/modells/CourseSyllabi/EDS%20216%20Lectures/2%20Cerebral%20Palsy%20and%20Spinal%20Cord%20Injury.ppt

Cerebral Palsy by Adele Anderson
http://www.plu.edu/~sope/Cerebral%20Palsy.ppt

The NJIT Robot Assisted Virtual Rehabilitation System by Laurie Roberts
www.ele.uri.edu/courses/ele482/S10/LaurieR_1.ppt

Assessment: Botulinum Neurotoxin for the Treatment of Autonomic Disorders and Pain, Movement Disorders, and Spasticity (An Evidence-Based Review) by American Academy of Neurology Therapeutics and Technology Assessment
Subcommittee
www.siumed.edu/neuro/AAA2010/documents/299.ppt

Read more...

31 October 2010

Neuroanatomical Techniques



Neuroanatomical Techniques

Presentation by
Armin Blesch, Ph.D.
Harvey Karten, M.D.

Objectives

Neuroanatomical techniques
History of modern neuroanatomy
Rudolf  Albert von Kölliker  (1817-1905)
nucleus  of Kölliker (Rexed  lamina X), continuity of axon and neuron
Heinrich  Wilhelm Gottfried Waldeyer (1837-1921)
Introduced  the term “neuron”  and “chromosome”

Camilio  Golgi   (1843-1926)
Golgi  method; Golgi cells;  Golgi apparatus; Golgi  tendon organ; Golgi-Mazzoni  corpuscle
Santiago  Ramon y Cajal (1852-1934)
Cajal's gold-sublimate method for astrocytes
horizontal  cell of Cajal (Retzius-Cajal cell in cortex
interstitial  nucleus of Cajal

Golgi Stain

Common immunohistochemical stains
Golgi: selective random neuron and fibers
Hematoxylin/Eosin: cell stain
Nissl (thionin): cell body stain
Kluver Barrera: mixed cell fiber stain
Weil: myelinated fiber stain
Acetycholine-esterase
Anterograde and Retrograde Tracing
Brief History of Tracing
(Grafstein, 1967)
(Kristensson & Olsson, 1971)
Fink-Heimer stain
(Heimer 1999)

Chromatolysis

http://cclcm.ccf.org/vm/VM_cases/neuro_cases_PNS_muscle.htm
Anterograde tracing with radioactive amino acids
Edwards and Hendrickson
in: Neuroanatomical tract tracing
Retrograde labeling of spinal motor neurons with HRP
Van der Want  et al.1997
Types of tracers
Application of tracers
Uptake Mechanisms
Active uptake:
Passive incorporation: lipophilic substances
Intracellular injection
Transport
Detection
Fluorescence
Enzyme reaction: HRP (WGA-HRP, CTB-HRP)
Antibodies e.g. CTB
Streptavidin-HRP conjugate for biotinylated tracers e.g. BDA, biocytin
Lectins and Toxins
WGA-HRP
Cholera Toxin beta subunit (CTB)
Retrograde, anterograde and transganglionic
Detection: antibody, HRP conjugate, conjugated to fluorophor
Application: 1 % aqueous solution, iontophoresis or pressure injection
Different efficiency in labeling among different neuronal populatioins and species
Transganglionic tracing of sensory axons with CTB
PHA-L
Anterograde tracing with PHA-L
Gerfen et al. in:
Neuroanatomical tract tracing
FITC/RITC
Fluoresceine isothiocyanate (FITC): green Rhodamine isothiocyanate (RITC): emission >590 nm (red)
Anterograde and retrograde transport
Pressure injection of 1-3% aqueous solution
Lipophilic Carbocyanine Dyes
Lipophilic Carbocyanine Dyes
Labeling of radial glia
Thanos et al. 2000
Dextran amines
Biotinylated dextran amine (BDA)
BDA
Reiner et al. 2000
Anterograde tracing of corticospinal axons
Biocytin/Neurobiotin
Application: 5% solution, pressure injection or iontophoresis
Fast degradation-short survival time 2-3 days
Mostly anterograde transport
Requires glutaraldehyde fixation
Retrograde tracers
All anterograde tracers are partially transported retrogradely
Purely retrograde tracers:
Fast Blue (FB)
Diamidino Yellow (DiY)
Microspheres
Edmund Hollis, UCSD
Scale bar 100 µm
Fluorogold
Fluorogold
Naumann et al. 2000
Ling Wang, UCSD
Cell filling
Viruses
Choosing the Right Tracer
Transgenic “Golgi” stains

GENSAT
 Objective: generate BAC-transgenic mice expressing GFP or CRE under the control of a gene specific promoter
 In situ Hybridization
 Emulsion Autoradiograpy
 Double labeling

Blurton-Jones et al
Blurton-Jones et al

Multiplex mRNA detection
Dave Kosman (Ethan Bier and Bill McGinnis labs, UC San Diego)
http://superfly.ucsd.edu/%7Edavek/images/quad.html
Immunohistochemistry
 Detection Methods
 TSA

Neuroanatomical Techniques.PPT

Read more...

03 April 2010

Parasitic Pathogens Affecting the CNS



Parasitic Pathogens Affecting the CNS
By:Mark F. Wiser
Department of Tropical Medicine
School of Public Health

Protozoa Affecting the CNS
Rare cases
Free-living ameba
Rare invasion of the brain
Entamoeba histolytica
Cerebral Malaria
Plasmodium falciparum
African Sleeping Sickness
African Trypanosomes
Associated with congenital defects and AIDS
Toxoplasma gondii
Disease

Protozoan
Amebas Affecting the CNS
* Entamoeba histolytica
o normally found in large intestine
o can become invasive (primarily liver)
* Free-living Amebas

GAE; skin or lung lesions
Balamuthia mandrillaris
GAE; skin or lung lesions; amebic keratitis
Acanthamoeba species
PAM

Naegleria fowleri
Diseases
Ameba

Toxoplasma gondii
* cosmopolitan distribution
* seropositive prevalence rates vary
o generally 20-75%
* generally causes very benign disease in immunocompetent adults
o congenital transmission
o AIDS associated
* tissue cyst forming coccidia
o predator-prey life cycle
o felines are definitive host
o infects wide range of birds and mammals (intermediate hosts)

Definitive Host
* adult forms
* sexual reproduction

Intermediate Host
* immature forms
* asexual reproduction

chronic stage = bradyzoites
acute stage = tachyzoites
* ingestion of sporulated oocysts (cat feces + incubation)
* ingestion of zoites (undercooked meat)
* congenital infection (only during acute stage)
* organ transplants
o chronic infection in donor
o immunosuppression
* blood transfusions (only during acute stage)

Human Transmission
Acquired Postnatal Toxoplasmosis
* 1-2 week incubation period
* acute parasitemia persists for several weeks until development of tissue cysts
o often asymptomatic (>80%)
o a common symptom is lymphadenopathy without fever
o occasionally mononucleosis-like (fever, headache, fatigue, myalgia)
* likely persists for life of patient
* immunosuppression can lead to reactivation (eg, organ transplants)

Congenital Toxoplasmosis
* 1o infection must occur during or shortly before pregnancy
o can only occur once
o 1/3 will pass infection to fetus
* incidence ~1 per 1000 births
* severity varies with age of fetus
o move severe early in pregnancy
o more frequent later in pregnancy
* infection can result in: spontaneous abortion, still birth, premature birth, or full-term Ä… overt disease
* typical disease manifestations include: retinochoroiditis, psychomotor disturbances, intracerebral calcification, hydrocephaly, microcephaly

Toxoplasmic Encephalitis
* common complication associated with AIDS during the 1980's
* recrudescence of latent infection
* multifocal disease associated with immunosuppression
* lesions detectable with CT or MRI
* little spread to other organs
* symptoms include: lethargy, apathy, incoordination, dementia
* progressive disease  convulsions
* usually fatal if untreated

Diagnosis
* various serological tests
* active (acute) vs chronic infection
o compare samples at 2 week intervals
o IgM > IgG; Ab titers
* seldom by direct parasite demonstration
o biopsy
o inoculation into mice or cell culture (only acute stage)
* CT scans or MRI for toxoplasmic encephalitis

Prevention
But dog contact is highly correlated with Toxoplasma transmission.
Several studies show no correlation between cat contact and Toxoplasma.

An Enigma
Some Helminths Affecting the CNS
Taenia solium and Cysticercosis
* adult tapeworm infects GI tract of humans
* larval stages infect tissues causing cysticercosis or neurocysticercycosis
* most common parasitic disease of the CNS
* endemic throughout much of the developing world
o especially prevalent in Central and South America, Sub-Saharan Africa, Southeast Asia and Central and Eastern Europe
* prevalence of 3.6% in some regions of Mexico
* greatest cause of acquired epilepsy worldwide

Cysticercosis in the United States
* has become an important parasitic disease, particularly in California
* estimated that 1000 new cases of neurocysticercosis will be diagnosed each year
* increasing prevalence attributed to the migration of large numbers of rural immigrants from developing countries
* also improvements in neuro-imaging leading to better diagnosis

http://www.dpd.cdc.gov/dpdx/
Disease States
* Taeniasis = adult tapeworm in small intestine
o Usually asymptomatic (eggs or proglottids in feces)
o Vague abdominal symptoms occasionally report
* Cysticercosis = T. solium larvae in human tissues (eg, muscle)
o Usually asymptomatic
o Painless subcutaneous nodules in arms and chest
* Neurocysticercosis (NCC) = cysts in the central nervous system
o Most severe manifestation

Pathogenesis of Cysticerci
* larva (cysticercal cysts) survive up to 5 years
* living larva produce little inflammation
* death of larva leads to inflammation and edema resulting in symptoms
* cellular reaction eventually destroys parasite and leaves a calcified nodule

Clinical Manifestations
* presentation is varied—depends on stage, number, size and location of cysts
* seizures/convulsions most common symptoms
* blocked circulation of CSF can lead to intracranial hypertension or hydrocephalus
* occasionally large cysts can mimic tumors
* can also cause a variety of mental and motor changes

Diagnosis
* onset of epileptic seizures
* person from endemic area
* CT scans and MRI are most useful
o 1-2 cm cystic lesions
o with or without edema and inflammation
* some serological tests available
o problems with sensitivity and specificity

Treatment
* symptomatic treatment (eg, antiepileptic drugs)
o spontaneous cures noted especially in children
* praziquantel and albendazole kill the cysts faster
o limited clinical benefit
o administer with corticosteroids (anti-inflammatory)
* surgical excision of cysts was previous treatment

Prevention and Control
* Enhanced personal hygiene
* Thorough cooking/ freezing of pork to kill cysticerci
* Enhanced environmental sanitation
o proper disposal of human feces
* Agricultural inspection of pork
* Vaccination of pigs?

Parasitic Pathogens Affecting the CNS.ppt

Read more...

Cysticcercosis



CYSTICERCOSIS
By:Palak Parikh

EPIDEMIOLOGY
* Found in approximately 50 million people worldwide (probably an underestimate)
* Endemic in several countries in Central and South America, sub-Saharan Africa, India, and Asia
* Prevalence in this country often higher in rural areas
* 221 deaths identified in the US from 1990-2002 (62% had emigrated from Mexico)

CYSTICERCOSIS TRANSMISSION
* Caused by the larval stage of Taenia solium, the pork tapeworm
* Humans develop by ingestion of T. solium eggs; they can spread infection by:
o Egg-containing feces contaminating water supplies in endemic areas
o Contaminating food directly, as eggs are sticky and can often be found under the fingernails of tapeworm carriers.

LIFE CYCLE
* Once eggs ingested, embryos are released in the small intestine and invade the bowel wall.
* They then disseminate hematogenously to other tissues and develop into cysticerci over 3 weeks to 2 months.
* Cysticerci – liquid-filled vesicles consisting of a membranous wall and a nodule containing the invaginated scolex.
* Scolex – head armed with suckers and hooks and a rudimentary body.

PATHOGENESIS
* Cysticerci initially viable but do not cause much inflammation in surrounding tissues – asymptomatic infection
* Host develops immune tolerance to cysticerci, which remain in this stage for several years.
o Postulated mechanisms of tolerance:
+ Taenia elaborate substances that inhibit or divert complement pathways away from parasite
+ Humoral antibodies do not kill mature taenia.
+ Poorly defined factors may interfere with lymphocyte proliferation and macrophage function, inhibiting normal cellular immune defenses.
* Clinical manifestations occur when inflammatory response develops around degenerating cysticercus.

SYMPTOMATIC DISEASE
* Divided into:
o Neurocysticercosis
o Extraneural cysticercosis

NEUROCYSTICERCOSIS
* 80% of infections are asymptomatic
* Symptoms mainly due to mass effect, inflammatory response, or obstruction of foramina and ventricular system of brain.
* Most common symptoms:
o Seizures
o Focal neurological signs
o Intracranial hypertension
* Peak estimated to occur 3-5 years after infection

NEUROCYSTICERCOSIS
* Increased risk of seizures with a single calcific granuloma.
* Risk of seizures highest when lesions are degenerating and are surrounded by inflammation.
* Encephalitis and diffuse brain edema most common in children and young females.
* 1-3% of cases involve the spinal cord, with thoracic lesions the most common.

NEUROCYSTICEROSIS IN ENDEMIC COUNTRIES
* Most common cause of adult-onset seizures
* Risk of seizures in seropositive individuals 2-3 times higher than seronegative controls.
* Punctate calcifications most frequent finding on neuroimaging of brain.

EXTRANEURAL CYSTICERCOSIS
* Typically involves:
o Eyes – in 1-3% of all infections
o Muscle
o Subcutaneous tissue – nodules most common in patients from Asia and Africa than from Latin America

DIAGNOSIS
* Serologic testing
* Peripheral eosinophilia only if cyst is leaking
* CT scan or MRI
o Pathognomonic Lesion: Scolex – mural nodule within a cyst
* Brain biopsy (only in symptomatic patients with equivocal serology and radiologic tests)

SEROLOGIC TESTING
* ELISA
* Complement fixation (CF)
* Radioimmunoassay
* Enzyme linked immunoelectrotransfer blot (EITB) assay – test of choice

EITB ASSAY
* Enzyme-linked immunoelectrotransfer blot assay
* Test of choice for detecting anticysticercal antibodies
* Uses affinity-purified glycoprotein antigens
* Higher sensitivity (83-100%) and specificity (93-98%) than ELISA
* Can be performed on serum or CSF but has a higher sensitivity on serum.
* Detected 94% of pathologically confirmed NCC with 2 or more lesions compared to only 28% with a single lesion in one study.

CT VS MRI
* MRI preferred since it is more sensitive in detecting:
o small lesions
o brainstem or intraventricular lesions
o perilesional edema around calcific lesions
o scolex
o degenerative changes in the parasite
* CT scan cheaper and better at detecting:
o small areas of calcifications.
o cysticercal infestation of extraocular muscles.

* Perform CT scan first followed by MRI in patients with inconclusive findings or in those with negative CT scans where strong clinical suspicion persists.

PERUVIAN STUDY
POTENTIAL TREATMENTS
* Albendazole (15 mg/kg/day) X 15 days + corticosteroids (30-40 mg prednisolone or 12-16 mg dexamethasone daily) – per UpToDate
* Praziquantel (50 mg/kg/day) X 15 days + corticosteroids (30-40 mg prednisolone or 12-16 mg dexamethasone daily) – per UpToDate
* Corticosteroids alone
* Anticonvulsants in patients who present with seizures or are at high risk for seizures
* Surgery

ALBENDAZOLE VS PRAZIQUANTEL
* Albendazole
o Destroys 75-90% of parenchymal brain cysts
o Does not interact with anticonvulsants
o Levels not adversely affected w/ co-administration of corticosteroids
* Praziquantel
o Destroys 60-70% of cysts 3 months after administration
o Decreased efficacy compared to Albendazole
o Available for oral administration
o Does not cross the blood-brain barrier well, so CSF levels only approx 20% of plasma levels.
o Involves cytochrome P-450 hepatic metabolism, which is induced by corticosteroids, phenytoin, and phenobarbital

* No blinded randomized controlled trials comparing albendazole to praziquantel.
Because of the above, praziquantel is generally considered second-line therapy.

TREATMENT
* One randomized, double-blind, placebo-controlled trial
o 120 pts with living cysticerci in the brain and seizures treated with antiepileptic drugs
+ Randomized to either albendazole (800 mg qd) and dexamethasone (6 mg qd X 10 days) or double placebo
+ Followed for 30 months or until they were seizure-free for 6 months after tapering of antiepileptic drugs
o Results:
+ Resolution of intracranial cystic lesions more common in treatment arm
+ Number of patients experiencing generalized seizures declined in the treatment arm
+ No significant change between the two groups in patients experiencing partial seizures

NEUROCYSTICERCOSIS
* Treatment in those with:
o 5-50 cysts (both antiparasitic and steroids)
o Steroids alone in patients w/ > 50 cysts
* No Treatment in those with:
o Asymptomatic nonviable neurocysticercosis
o Calcified cysts
o Single viable cysts
o Fewer than 5 cysts

ANTICONVULSANTS
* Recommended for patients who present with seizures
* Should be stopped if patient remains seizure-free during therapy to see if the patient remains asymptomatic
* Should be reinitiated chronically if the patient has recurrent seizures
* Should be considered in patients w/ multiple cysts who have no history of seizure activity

SURGICAL INTERVENTION
* Used in some patients with intracranial hypertension
* Shunting improves hydrocephalus, although recurrent blockages of shunts common
* Surgical intervention recommended for cysts:
o Located in the 4th ventricle
o Attached to middle cerebral artery
o Compressing the optic chiasm
o Located in the spine

TREATMENT OF EXTRANEURAL CYSTICERCOSIS
* None if pt asymptomatic
* Surgical excision for intraocular disease
* Medical therapy for involvement of extraocular muscles or optic nerve.
* NSAIDs for patients w/ symptomatic subcutaneous or intramuscular lesions.
* Excision of solitary lesions if NSAIDs fail or not tolerated.

BEFORE INITIATING MEDS…
* Apply PPD.
* Consider treating with a single dose of ivermectin before beginning corticosteroids, as many patients have risk factors for strongyloidiasis.
* Consult ophthalmology to rule out ocular cysticercosis.

PATIENT MONITORING
* Intermittent surveillance w/ imaging until cyst(s) resolve(s).
o Perhaps every 3-6 months if patient improving or earlier if patient symptomatic.
* Reimaging of brain 2 months after completion of treatment
* Consider antiparasitic therapy if cysts growing off therapy

POSSIBLE PREVENTION
* Human Tapeworm Infections
o Inspection of pork for cysticerci
o Freezing or adequately cooking meat to destroy cysticerci
o Administering antiparasitic agents to pigs
* Infection in Pigs
o Confining animals and not allowing them to roam freely
o Improved sanitary conditions
* Egg Transmission to Humans
o Good personal hygiene and hand washing prior to food preparation
o Identifying human carriers of tapeworms
o Mass community programs to treat tapeworm carriers.
* Possible Vaccine – porcine vaccine currently in the works

TAKE HOME POINTS
* Cysticercosis caused by the larval stage of Taenia solium, the pork tapeworm
* Pay special attention if pt from Central and South America, sub-Saharan Africa, India, and Asia, as neurocysticercosis is the most common cause of adult-onset seizures in these endemic areas.
* Order Head CT first to diagnose neurocysticercosis; if negative and suspicion still high, order Brain MRI.
* EITB test of choice for serology.
* Place PPD before starting treatment.
* Obtain Ophthalmology consult before starting treatment.
* Albendazole and Dexamethasone comprise first-line treatment for symptomatic cysticercosis. Consider concurrent anticonvulsants if pt presents with seizures.

REFERENCES
* aapredbook.aappublications.org
* UpToDate.
* www.dpd.cdc.gov
* www.e-radiology.net
* www.parasite-diagnosis.ch
* www.stanford.edu/class/cysticercosis/symptoms

CYSTICERCOSIS.ppt

Read more...

02 April 2010

The Basal Ganglia



The Basal Ganglia

Outline
* Components of the basal ganglia
* Arrangement of basal ganglia components in the brain
* Architecture: cytology & neurochemistry
* Pathways & circuitry
* Function(s) of the basal ganglia
* Dysfunction and pathology
* Differences between human and rodent basal ganglia?

What are the Basal Ganglia?
The basal ganglia include…
* Neostriatum
o Caudate nucleus
o Putamen
o Nucleus Accumbens
* Globus Pallidus
o Internal segment
o External segment
o Ventral pallidum
* Subthalamic nucleus
* Substantia nigra
o Pars compacta
o Pars reticulata
* Pedunculopontine nucleus**
Subgroups of the basal ganglia
* Striatum
o Caudate nucleus
o Putamen
* Lenticular nuclei
o Globus pallidus
o Putamen
* Corpus striatum
o Caudate
o Lenticular nuclei

How are the basal ganglia arranged in the brain?
Caudate Nucleus
o C shaped structure
o Lateral wall of lateral ventricle
o Head, body and tail of caudate

Putamen and Globus Pallidus
* Putamen + Globus Pallidus = lentiform or lenticular nuclei
* Fills in space between the inferior horn and the anterior horn and body of the lateral ventricle.
* Gap between the lentiform nuclei and the lateral ventricle filled by the caudate nucleus.
* The posterior limb of the internal capsule separates the lentiform nuclei from the thalamus.

* Claustrum
* Septum pellucidum
* Insular cortex
* Corpus callosum
* Caudate nucleus
* Putamen
* Nucleus accumbens
* Internal capsule
* External capsule
* Extreme capsule
* Caudate nucleus
* Putamen
* Globus pallidus external (GPe)
* Globus pallidus internal (GPi)
* Ventral pallidum
* Anterior commissure
* Substantia innominata
* Internal capsule
* Lentiform nucleus**
* Caudate (Head, body, tail)
* Putamen
* GPe & GPi
* Lateral ventricle, anterior and temporal horn
* Internal capsule, anterior and posterior horn
* Caudate nucleus (body and tail)
* Putamen
* Globus pallidus
* Subthalamic nucleus
* Substantia nigra

- Pars compacta
- Pars reticulata
* Subthalamic nucleus
* Substantia nigra
* Globus pallidus external
* Subthalamic nucleus
* Substantia nigra
* Ventral tegmental area

Functions of the Basal Ganglia
* Extrapyramidal motor system
* Motor planning, sequencing and learning
* Striatal neuronal activity is not sufficiently explained by the stimuli presented or the movements performed
* Dependent on certain behavioral situations, certain conditions or particularly types of trials
+ -sensory stimuli but only when they elicit movements
+ -instruction cues (go-no go)
+ -memory related cues
+ -reward (especially ventral striatum)
+ -self-initiated moves
* Basal ganglia distinguished from cerebellum by connections with limbic system

Architecture of the basal ganglia: cellular and neurochemistry

Cytoarchitecture
* Main neurotransmitter in basal ganglia is GABA
* 95% of neurons in neostriatum are medium spiny neurons
o Contain GABA
o Principal neurons: project to globus pallidus and SNpr
o Subpopulations are distinguished by peptides, neurotransmitter receptors and connections
o Receive bulk of afferent input
* Several populations of interneurons
o aspiny
o ACh, somatostatin, GABA/parvalbumin
Neuronal circuitry of the basal ganglia
The Neostriatal Mosaic
* Neostriatum divided into two compartments:
patch (striosome) & matrix
* First described by Ann Graybiel in 1978 using AChE stain
* Not visible in Nissl stains (“hidden chemoarchitecture”)
* Define input/output architecture of neostriatum

Neostriatal Mosaic and Input/Output Organization
* Most inputs to the neostriatum terminate in a patchy fashion (“matrisomes”)
* Input from a given cortical region terminates over an extended anterior-posterior extent
* Functionally related cortical areas project to the same patches
* Output neurons to a given efferent subregion are also arranged in patches
* Neurons in patches project to both GPi/SNpr and GPe

Functional subdivisions
* Sensorimotor
o Putamen + globus pallidus/SNpr
o SNpc
* Association
o Caudate nucleus + globus pallidus/SNpr
o SNpc
* Limbic
o Nucleus accumbens + ventral pallidum
o VTA

Basal ganglia connections and pathways
Connections
* Afferents/inputs (neostriatum):
o Cerebral cortex (entire cortex)
o Thalamus (intralaminar and midline nuclei)
o Amygdala (basolateral nucleus)
o Raphe, substantia nigra pars compacta, VTA
* Efferents/output (GPi, VP, SNpr)
o Ventral tier nuclei of thalamus
o Subthalamic nucleus
o Superior colliculus
Organization of inputs to basal ganglia
Organization of basal ganglia outputs

All regions of cerebral cortex project to the basal ganglia, but output of basal ganglia is directed towards the frontal lobe, particularly pre-motor and supplementary motor cortex
Basic Circuit of Basal Ganglia

Neostriatum
GPi/SNpr
Cerebral Cortex
VA/VL thalamus
Direct vs. indirect pathways
* Different populations of spiny neurons
* Neuromodulators/co-transmitters
* Striosomes vs. matrix
* Dopamine receptor subtypes
Both

Recurrent loops
* Motor loop
o sensorimotor areas 1,2,3,4,5,6 -> putamen -> GP -> VA ->SMA
* Ocularmotor loop
o prefrontal cortex & ppc 9,12, 7 -> caudate -> GP -> VA -> frontal eye fields & SC
* Cognitive loop
o prefrontal cortical areas 9,12 -> caudate -> GP -> VA -> prefrontal cortex
* Limbic loop
o cingulate -> caudate (striosomes)-> GP -> MD -> ant. cingulate.
Topography is maintained within each loop!

Motor loop
Somatotopic subdivisions of the input remain segregated throughout the circuit.
Adapted from Rothwell, 1994; from Alexander and Crutcher, 1990
Processing in the basal ganglia
Huntington’s and Parkinson’s diseases
* Neurodegenerative diseases
* Motor dysfunction
* Brainwide pathology with focus on basal ganglia elements
* Genetic and/or environmental causes
Huntington’s Disease
Clinical symptoms
* Hyperkinetic & hemiballistic movements

Pathology hallmarks
* Striopallidal degeneration
* Decreased striatal volume
* Decrease in 5-HT1B receptors in ventral pallidum
Hyperkinetic hypothesis
* Reduced Glu (+) from STN to GPi, due either to STN lesions or reduced striatopallidal inhibitory influences along the in direct pathway lead to reduced inhibitory outflow from GPi/SNr and excessive disinhibition of the thalamus.
* Increased Glu (+) to cortical areas engaged by the motor circuit (SMA, PMC, MC) results in hyperkinetic movements.
Parkinson’s Disease
Clinical symptoms
* Hypokinetic movement
* Cogwheel rigidity

Pathology hallmarks
* Nigostriatal degeneration
* DA neuronal degeneration in SN
Hypokinetic hypothesis
* Inhibition of GPe within the indirect pathway leads to disinhibition of the STN
* Increased STN to the basal ganglia output nuclei (Gpi/SNr), leads to excessive thalamic inhibition.
* This is reinforced by reduced inhibitory input to Gpi/SNr through the direct pathway.
* Overall result is a reduction in reinforcing influence of the motor circuit upon cortically initiated movements.

PD Therapeutics: The approaches
* Pharmacology
o DA, mGluR, MAO(B) inhibitors, antioxidants, iron chelators
* Surgical
o Pallidal ablation
o DBS of globus pallidus or STN
* Transplantation
o Fibroblast cells
o Stem cells
* Vaccines
* RNA interference (RNAI)-based treatments

DBS: Deep Brain Stimulation of STN
Common themes in neurodegeneration
* Neurotoxicity
* Inflammation (glia)
* Apoptosis
* Abnormal protein aggregation
Thank you!
Notable differences between basal ganglia of human and rodents …..
There are differences in:
* Divisions & nomenclature
* Proportions
* Topography of afferent and efferent projections
Globus pallidus and entopeduncular nucleus (rodent)
vs.
Globus pallidus (external) and Globus pallidus (internal) (primate)
Regional proportion by volume
(% of total volume)
Spinal Cord

Major projection differences

* Neurons projecting to the motor and associative striatum
o Rats: reside in distinct regions
o Primates: arranged in interdigitating clusters.
* Terminal fields of projections arising from the motor and associative striatum
o rats: largely segregated
o Primates: not segregated
* Organization of patch- and matrix-projecting dopamine cells
o Rats: organized in spatially, morphologically, and histochemically distinct ventral and dorsal tiers,
o Primates: no (bi)division of the dopaminergic system that results in two areas which have all the characteristics of the two tiers in rats.

The Basal Ganglia.ppt
http://login.ncmir.ucsd.edThe Basal Ganglia

Outline
* Components of the basal ganglia
* Arrangement of basal ganglia components in the brain
* Architecture: cytology & neurochemistry
* Pathways & circuitry
* Function(s) of the basal ganglia
* Dysfunction and pathology
* Differences between human and rodent basal ganglia?

What are the Basal Ganglia?
The basal ganglia include…
* Neostriatum
o Caudate nucleus
o Putamen
o Nucleus Accumbens
* Globus Pallidus
o Internal segment
o External segment
o Ventral pallidum
* Subthalamic nucleus
* Substantia nigra
o Pars compacta
o Pars reticulata
* Pedunculopontine nucleus**
Subgroups of the basal ganglia
* Striatum
o Caudate nucleus
o Putamen
* Lenticular nuclei
o Globus pallidus
o Putamen
* Corpus striatum
o Caudate
o Lenticular nuclei

How are the basal ganglia arranged in the brain?
Caudate Nucleus
o C shaped structure
o Lateral wall of lateral ventricle
o Head, body and tail of caudate

Putamen and Globus Pallidus
* Putamen + Globus Pallidus = lentiform or lenticular nuclei
* Fills in space between the inferior horn and the anterior horn and body of the lateral ventricle.
* Gap between the lentiform nuclei and the lateral ventricle filled by the caudate nucleus.
* The posterior limb of the internal capsule separates the lentiform nuclei from the thalamus.

* Claustrum
* Septum pellucidum
* Insular cortex
* Corpus callosum
* Caudate nucleus
* Putamen
* Nucleus accumbens
* Internal capsule
* External capsule
* Extreme capsule
* Caudate nucleus
* Putamen
* Globus pallidus external (GPe)
* Globus pallidus internal (GPi)
* Ventral pallidum
* Anterior commissure
* Substantia innominata
* Internal capsule
* Lentiform nucleus**
* Caudate (Head, body, tail)
* Putamen
* GPe & GPi
* Lateral ventricle, anterior and temporal horn
* Internal capsule, anterior and posterior horn
* Caudate nucleus (body and tail)
* Putamen
* Globus pallidus
* Subthalamic nucleus
* Substantia nigra

- Pars compacta
- Pars reticulata
* Subthalamic nucleus
* Substantia nigra
* Globus pallidus external
* Subthalamic nucleus
* Substantia nigra
* Ventral tegmental area

Functions of the Basal Ganglia
* Extrapyramidal motor system
* Motor planning, sequencing and learning
* Striatal neuronal activity is not sufficiently explained by the stimuli presented or the movements performed
* Dependent on certain behavioral situations, certain conditions or particularly types of trials
+ -sensory stimuli but only when they elicit movements
+ -instruction cues (go-no go)
+ -memory related cues
+ -reward (especially ventral striatum)
+ -self-initiated moves
* Basal ganglia distinguished from cerebellum by connections with limbic system

Architecture of the basal ganglia: cellular and neurochemistry

Cytoarchitecture
* Main neurotransmitter in basal ganglia is GABA
* 95% of neurons in neostriatum are medium spiny neurons
o Contain GABA
o Principal neurons: project to globus pallidus and SNpr
o Subpopulations are distinguished by peptides, neurotransmitter receptors and connections
o Receive bulk of afferent input
* Several populations of interneurons
o aspiny
o ACh, somatostatin, GABA/parvalbumin
Neuronal circuitry of the basal ganglia
The Neostriatal Mosaic
* Neostriatum divided into two compartments:
patch (striosome) & matrix
* First described by Ann Graybiel in 1978 using AChE stain
* Not visible in Nissl stains (“hidden chemoarchitecture”)
* Define input/output architecture of neostriatum

Neostriatal Mosaic and Input/Output Organization
* Most inputs to the neostriatum terminate in a patchy fashion (“matrisomes”)
* Input from a given cortical region terminates over an extended anterior-posterior extent
* Functionally related cortical areas project to the same patches
* Output neurons to a given efferent subregion are also arranged in patches
* Neurons in patches project to both GPi/SNpr and GPe

Functional subdivisions
* Sensorimotor
o Putamen + globus pallidus/SNpr
o SNpc
* Association
o Caudate nucleus + globus pallidus/SNpr
o SNpc
* Limbic
o Nucleus accumbens + ventral pallidum
o VTA

Basal ganglia connections and pathways
Connections
* Afferents/inputs (neostriatum):
o Cerebral cortex (entire cortex)
o Thalamus (intralaminar and midline nuclei)
o Amygdala (basolateral nucleus)
o Raphe, substantia nigra pars compacta, VTA
* Efferents/output (GPi, VP, SNpr)
o Ventral tier nuclei of thalamus
o Subthalamic nucleus
o Superior colliculus
Organization of inputs to basal ganglia
Organization of basal ganglia outputs

All regions of cerebral cortex project to the basal ganglia, but output of basal ganglia is directed towards the frontal lobe, particularly pre-motor and supplementary motor cortex
Basic Circuit of Basal Ganglia

Neostriatum
GPi/SNpr
Cerebral Cortex
VA/VL thalamus
Direct vs. indirect pathways
* Different populations of spiny neurons
* Neuromodulators/co-transmitters
* Striosomes vs. matrix
* Dopamine receptor subtypes
Both

Recurrent loops
* Motor loop
o sensorimotor areas 1,2,3,4,5,6 -> putamen -> GP -> VA ->SMA
* Ocularmotor loop
o prefrontal cortex & ppc 9,12, 7 -> caudate -> GP -> VA -> frontal eye fields & SC
* Cognitive loop
o prefrontal cortical areas 9,12 -> caudate -> GP -> VA -> prefrontal cortex
* Limbic loop
o cingulate -> caudate (striosomes)-> GP -> MD -> ant. cingulate.
Topography is maintained within each loop!

Motor loop
Somatotopic subdivisions of the input remain segregated throughout the circuit.
Adapted from Rothwell, 1994; from Alexander and Crutcher, 1990
Processing in the basal ganglia
Huntington’s and Parkinson’s diseases
* Neurodegenerative diseases
* Motor dysfunction
* Brainwide pathology with focus on basal ganglia elements
* Genetic and/or environmental causes
Huntington’s Disease
Clinical symptoms
* Hyperkinetic & hemiballistic movements

Pathology hallmarks
* Striopallidal degeneration
* Decreased striatal volume
* Decrease in 5-HT1B receptors in ventral pallidum
Hyperkinetic hypothesis
* Reduced Glu (+) from STN to GPi, due either to STN lesions or reduced striatopallidal inhibitory influences along the in direct pathway lead to reduced inhibitory outflow from GPi/SNr and excessive disinhibition of the thalamus.
* Increased Glu (+) to cortical areas engaged by the motor circuit (SMA, PMC, MC) results in hyperkinetic movements.
Parkinson’s Disease
Clinical symptoms
* Hypokinetic movement
* Cogwheel rigidity

Pathology hallmarks
* Nigostriatal degeneration
* DA neuronal degeneration in SN
Hypokinetic hypothesis
* Inhibition of GPe within the indirect pathway leads to disinhibition of the STN
* Increased STN to the basal ganglia output nuclei (Gpi/SNr), leads to excessive thalamic inhibition.
* This is reinforced by reduced inhibitory input to Gpi/SNr through the direct pathway.
* Overall result is a reduction in reinforcing influence of the motor circuit upon cortically initiated movements.

PD Therapeutics: The approaches
* Pharmacology
o DA, mGluR, MAO(B) inhibitors, antioxidants, iron chelators
* Surgical
o Pallidal ablation
o DBS of globus pallidus or STN
* Transplantation
o Fibroblast cells
o Stem cells
* Vaccines
* RNA interference (RNAI)-based treatments

DBS: Deep Brain Stimulation of STN
Common themes in neurodegeneration
* Neurotoxicity
* Inflammation (glia)
* Apoptosis
* Abnormal protein aggregation
Thank you!
Notable differences between basal ganglia of human and rodents …..
There are differences in:
* Divisions & nomenclature
* Proportions
* Topography of afferent and efferent projections
Globus pallidus and entopeduncular nucleus (rodent)
vs.
Globus pallidus (external) and Globus pallidus (internal) (primate)
Regional proportion by volume
(% of total volume)
Spinal Cord

Major projection differences

* Neurons projecting to the motor and associative striatum
o Rats: reside in distinct regions
o Primates: arranged in interdigitating clusters.
* Terminal fields of projections arising from the motor and associative striatum
o rats: largely segregated
o Primates: not segregated
* Organization of patch- and matrix-projecting dopamine cells
o Rats: organized in spatially, morphologically, and histochemically distinct ventral and dorsal tiers,
o Primates: no (bi)division of the dopaminergic system that results in two areas which have all the characteristics of the two tiers in rats.

The Basal Ganglia.ppt

Read more...

Anxiety Disorders



Anxiety Disorders

* Panic disorder
o Can be induced by lactate or CO2 in PD sufferers (only occasionally in normal people)
o Increased activity in parahippocampal gyrus,
o Decreased activity in anterior temporal cortex & amygdala (seems odd!)
o May have 3, rather than 2, repeats of a section on chromosome 15
+ Also have joint laxity (bend too far)

* Treatments for panic disorder
o Benzodiazepines (e.g., Valium)
+ Increase frequency of Cl- channel openings in response to GABA
+ Have little or no effect alone: safer than barbiturates
+ Allopregnanolone = endogenous agonist at benzodiazepine binding site.
o Buspirone (Buspar): 5-HT1a agonist (GI/O)
o SSRIs: fluoxetine (Prozac), paroxetine (Paxil)

Benzodiazepine receptors in brain
PTSD
* Monozygotic > dizogotic concordance
o Genetics 1/3 of variance
* NMDA mechanisms in amygdala
o May mediate both the conditioning and the extinction
+ NMDA antagonists in amygdala prevent extinction
+ Hippocampus and PFC also lose effectiveness in extinction
* Not due to high levels of glucocorticoids:
o Usually PTSD sufferers have LOWER than normal cortisol levels, despite high CRH
+ Maybe it’s the high CRH that  symptoms
+ Or maybe it’s increased responsiveness to CRH or cortisol
* Individual differences in responsiveness to trauma
* Sometimes treated with β NE antagonists (propranolol) or protein synthesis inhibitors soon after the trauma or during recall of the trauma
OCD
* Increased metabolism in orbitofrontal cortex, cingulate, and caudate nuclei.
* Decreased REM latency (~ to depression)
* At least 2 gene polymorphisms:
o For BDNF, 5-HT2A receptor
* Treatment: SSRIs
Cingulotomy to treat OCD
Tourette’s Syndrome
* In many ways opposite Parkinson’s disease
* Treated with dopamine antagonists
* Monozygotic concordance: 53-77%; dizygotic concordance: 8-23%
* Witty Ticcy Ray (by Oliver Sacks): “We Touretters…are forced into levity by our Tourette’s and forced into gravity when we take Haldol….You have a natural balance: we must make the best of an artificial balance.”

THE NIGROSTRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS
* Nigrostriatal and mesolimbic tracts are parallel.
o Begin in midbrain (substantia nigra & ventral tegmental area, VTA)
o End in dorsal (caudate & putamen) and ventral (N. accumbens) striatum
o Cortico-striato-pallido-thalamic-cortical loops

Nigrostriatal system
* Plans and triggers self-initiated movements
* Adjusts posture
* Degeneration  Parkinson’s disease
o Tremor at rest
o Difficulty initiating movements

Mesolimbic system
* Increases responsiveness to external and internal stimuli
* Motivation
* Motor activity
* Reward
* Drug addiction
* Schizophrenia
Nigrostriatal dopamine tract
Mesolimbic dopamine tract

Direct pathway
* Positive feedback loop
* Cortical areas that initiated the activity are further excited.
* 2 consecutive inhibitory influences
* Then an excitatory influence
* Stimulating the first inhibitory path inhibits the second inhibitory path: disinhibits the excitatory path.

Sensorimotor Cortex
Striatum
Direct pathway
* Stimulate putamen
* Inhibits GPi/SNr
via D1 receptors
Sensorimotor Cortex
Striatum
Direct Pathway
When putamen inhibits
GPi/SNr, VL/VA
is disinhibited.
Thus, VL/VA excites
sensory motor cortex.
Indirect Pathway
Negative feedback
Begins with 2
inhibitory paths:
1. Putamen to GPe
2. GPe to STN
Sensorimotor Cortex
Indirect Pathway
Those inhibitory paths disinhibit an excitatory path.
But that exc. path ends on another inhibitory path!
Function
* Direct path excites cortex; indirect path inhibits it: opposing functions.
* May “sharpen” influence on behavior
o (similar to “sharpening” receptive fields).
* May provide greater control over movement
o (similar to having both EPSPs and IPSPs on same neuron).

Effects of Dopamine
* D1 receptors excite the Direct Pathway
o (i.e., increase excitation of the cortex).
* D2 receptors inhibit the Indirect Pathway
o (i.e., decrease the inhibition of thalamus and therefore increase excitation of cortex).
* Therefore, both effects increase excitation of cortex
o (i.e., increase either movement or motivation).

The Mesolimbic System
* Circuit is parallel to nigrostriatal system:
o Direct and indirect pathways
o Prefrontal cortex vs. sensory motor
o N. accumbens (ventral striatum), vs. caudate & putamen (dorsal striatum)
o Ventral pallidum vs. GPi and GPe
o Mediodorsal thalamus vs. VL/VA
Prefrontal Cortex
VP normally inhibits

Effects of Dopamine
* D1 receptors excite the Direct Pathway
o (i.e., increase excitation of the cortex).
* D2 receptors inhibit the Indirect Pathway
o (i.e., decrease the inhibition of thalamus and therefore increase excitation of cortex).
* Therefore, both effects increase excitation of cortex
o (i.e., increase either movement or motivation).

Glutamate/DA balance in schizophrenia
* Cortical or hippocampal hypofunction may  decrease glutamate in NAcc and striatum
* decrease tonic DA release
* increase DA receptor sensitivity
* hyperresponsive to phasic input

Anxiety Disorders.ppt

Read more...

Movement Disorders



Movement Disorders

* Background
o AKA Extrapyramidal Disorders
o These disorders impair the regulation of voluntary motor activity w/o affecting the strength, sensation, or cerebellar fcn.
o Result from dysfunction of the basal ganglia
+ Caudate
+ Putamen
+ Globus Pallidus
+ Subthalamic Nucleus
+ Substantia Nigra
+ Lentiform Nucleus
# Putamen & Globus Pallidus
+ Corpus Striatum
# Lentiform Nucleus + Caudate Nucleus
* Basal Ganglia Circuitry (Fig 7-1)
o Corticocortical Loop:
Cerebral Cortex
Caudate & Putamen
Internal Segment
Globus Pallidus
Thalamus
* Basal Ganglia Circuitry (Fig 7-1)
o Nigrostriatal Loop:
Substantia Nigra
Caudate & Putamen
* Basal Ganglia Circuitry (Fig 7-1)
o Striatalpallidal Loop:
Caudate & Putamen
External Segment
Globus Pallidus
Subthalamic Nuclei
Internal Segment
Globus Pallidus
* Types of Abnormal Movements
o Tremor: rhythmic movement characterized by when it occurs
+ Postural Tremor
# During sustained posture
+ Intention Tremor
# During movement; absent at rest
+ Resting Tremor
# At rest
o Chorea: irregular muscle jerks
+ Florid Cases
# Fully developed
# Forceful movements of limbs, head, facial grimacing, & tongue movements
+ Mild Cases
# Characterized by:
* Clumsiness
* Milkmaid grasp
* Absent in sleep
o Hemiballismus
+ Unilateral Chorea
+ Involves the proximal muscles
+ Vascular disease of contralateral subthalamic nucleus
o Athetosis
+ Continued slow, sinuous, & writhing movements
o Dystonia: sustained athetotic movements
+ Segmental Dystonia
# Affects one or more limbs
+ Focal Dystonia
# Affects localized muscle groups
+ Palliative/Provocative
+ Causes
o Myoclonus
+ Definition
+ Classification
+ Generalized: widespread
# Physiological
# Essential
# Epileptic
# Symptomatic
+ Segmental: more localized
o Tics
+ Definition
+ Palliative/Provocative
+ Types
# Transient Simple: common in children, resolve w/I 1 yr
# Chronic: any age, no tx
# Persistent Simple or Multiple: onset before 15 yoa, resolve in adults
# Chronic Multiple: Tourette’s Sydrome
* Hypokinetic Movement Disorders
o Parkinson’s Disease
* Hyperkinetic Movement Disorders
o Huntington’s Disease
o Wilson’s Disease
o Tourette’s Syndrome
o Restless Leg Syndrome
* Parkinson’s Disease - Hypokinetic
o Defined as a syndrome consisting of variable combination of tremor, rigidity, bradykinesia, and characteristic disturbance of gait and posture
o Onset: mid-late life; mean age is 57 yrs
o Epidemiology:
+ Affects all ethnicities
+ has equal M/F distribution
+ occurs 1-2 per 1,000 people in general population
+ occurs 1 per 100 people that are over 65 yrs
+ 4th most common disease in the elderly
* Parkinson’s Disease - Hypokinetic
o Cause: unknown
o Pathophysiology:
+ Loss of dopaminergic cells in the substantia nigra
# Dopamine’s normal function
+ Over excitation of the caudate & putamen
+ Over excitation of the corticospinal tracts
+ Oscilation of feedback
+ Decrease in thalamic excitation of the motor cortex
o Four Hallmark Signs
+ Resting Tremor (Pill-Rolling)
+ Rigidity (Lead-Pipe or Cogwheel)
+ Bradykinesia
+ Flexed Posture with shuffling gait (Festinating)
o Examination:
+ History
+ Phsyical Findings:
# Passive movement
# Muscle Strength
# Sensory
# Deep Tendon Reflexes
# Autonomic
# Myerson’s Sign
# Pull Test
o Diagnosis:
+ Four Hallmark signs
+ Tremor is absent in 30% of patients
o Differential Diagnosis
+ Involuntary tremor vs. Intentional tremor
+ Depression
+ Wilson’s Disease
+ Huntington’s Disease
o A neurodegenerative disorder which predominately has behavioral, cognitive, or signs
o Onset: Usually begins during adult life
o Epidemiology:
+ 5-10 per 100,000 in the US
+ 50% chance to pass on the disorder
+ Anticipation
+ Paternal Descent
* Huntington’s Disease – Hyperkinetic
o Cause: Autosomal Dominant Disorder
o Pathophysiology:
+ Mutation on chromosome 4: CAG repeats
+ CAG Normal Function: codes for glutamine
+ Over-expression of the gene: i.e. excess glutamine
+ Uncertainty?
* Huntington’s Disease – Hyperkinetic
o Cause: Autosomal Dominant Disorder
o Pathophysiology:
+ Pathological Changes
# Atrophy & neuronal degeneration of cortex
# Hallmark: caudate atrophy
+ Projected Conclusion?
# Over activity
# Under activity
o Examination:
+ Physical Findings
# Initial Findings
* Gradual onset
* Slowed saccadic movements 1st sign
* In 85% chorea is predominate movement disorder
# Juvenile Form
* AKA The Westphal Variant
* Rigidity & bradykinesia
* Tremors, Dystonic postures, & Ataxia
* Mental retardation, Seizures, & myoclonus
o Examination:
+ Physical Findings
# Adult Onset
* Prominent chorea
* Bradykinesia
* Postural reflex compromise
# Terminal Phase
* Dysarthria, dysphagia, & respiratory difficulties
# General
* Cognitive impairment
* Depression
* Psychiatric disorders
* Wilson’s Disease – Hyperkinetic
o Onset
+ Hepatic Dysfunction – 11 yoa
+ Neurological Dysfunction – 19 yoa
o Epidemiology
+ Rare
+ 1 in 40,000 people
o Cause: Autosomal Recessive Disorder
o Pathophysiology
+ Abnormal copper metabolism
+ Deposition of copper in tissues
o Examination
+ Physical Findings
# Children: hepatic dysfunction predominates
* Sardonic Smile
* Behavioral problems
# Adults: neurological dysfunction predominates
* Parkinsonian features
# General
* Hallmark: Kayser-Fleischer Rings
* 1/3 experience psychiatric symptoms
* Other ocular abnormalities
* Gilles de la Tourette Syndrome – Hyperkinetic
o Diagnosed when childhood onset tics are multifocal, motor or vocal, lasting longer than 1 yr and naturally wax and wane
o Cause: unknown
o Onset: 2-21 yoa
o Male predilection
* Gilles de la Tourette Syndrome – Hyperkinetic
o Examination
+ Physical Findings
# Simple Tics
* Motor: blinking, facial grimacing, shoulder shrugging
* Vocal: throat clearing, grunting, snorting, barking
# Complex Tics
* Motor: hopping, skipping, Echopraxia
* Vocal: Coprolalia, Echolalia, Palilalia
* Restless Legs Syndrome – Hyperkinetic
o Common movement disorder
o Diagnostic Criteria
# Desire to move limbs which is associated with unpleasant sensations
# Restlessness
# Worsening of symptoms @ rest w/ temporary relief w/ movement
# Worsening of symptoms @ night
* Restless Legs Syndrome – Hyperkinetic
o Common Descriptions
+ Always unpleasant, but not necessarily painful
+ Need to move
+ Crawling
+ Tingling
+ Itching
+ Restless

Movement Disorders.ppt

Read more...

23 October 2009

Myasthenia Gravis



Myasthenia Gravis
By:
* Cathie Rohleder
* Sydnee Jacobson
* Ashley Cox

Pathology
* A chronic Autoimmune Disease
* Affects the Neuromuscular junction
* Postsynaptic acetylcholine receptors on muscle cells plasma membrane are no longer recognized as ‘self’ and elicit the generation of auto antibodies.
* IgG antibody is produced against the acetylcholine receptors and fixes to receptor sites, blocking the binding of acetylcholine.
* Diminished transmission and lack of muscular depolarization results.
* Several Types of Myasthenia Gravis
o Neonatal Myasthenia Gravis: A transient condition in 10% to 15% of infants born to mothers with MG.
o Congenital Myasthenia
o Juvenile Myasthenia: Onset is around 10 years of age.
o Ocular Myasthenia
o Generalized Autoimmune Myasthenia

Clinical Manifestations
* Insidious onset
o May first appear during pregnancy, during the postpartum period, or in combination with the administration of anesthetic agents.
* Complaints
o Most individuals complain of fatigue and progressive weakness.
o The person usually has a history of frequent respiratory tract infections.
* Muscles affected
o First muscles affected
+ Muscles of the eyes, mouth, face, throat and neck.
+ The most affected muscles are the extra ocular (eye) muscles and levator muscles.
o Second most affected muscles
+ Muscles of mastication, swallowing, facial expression, and speech.
o Less frequently affected muscles
+ Neck, shoulder girdle, and hip flexors
o All muscles are weak in the advanced stage of the disease.
* Other occurrences
o Myasthenic Crisis happens when extreme muscle weakness causes quadriparesis or quadriplegia, difficulty swallowing, and shortness of breath. A person in this state is in danger of respiratory arrest.
o Cholinergic Crisis occurs from anticholinesterase drug toxicity. This is similar to Myasthenic Crisis, but also includes increased intestinal motility with diarrhea and complaints of cramping, fasciculation, bradycardia, constriction of the pupils, increased salvation, and sweating. A person in this state may also be in danger of respiratory arrest.

Treatment
* Surgery
o Thymectomy: removal of the thymus gland
o A tumor is usually present in the thymus gland

* Medication
o Cholinesterase inhibitors
+ These include neostigmine and pyridostigmine
+ Helps improve neuromuscular transmission and increase muscle strength
o Immunosuppressive drugs
+ These include prednisone, cyclosporine, and azathioprine
+ Improves muscle strength by suppressing the production of abnormal antibodies
o Corticosteroids
+ Inhibits the immune system
+ Limits antibody production.
* Plasmapheresis
o remove abnormal antibodies from the blood
o Used for more serious conditions.
o Benefits last around a few weeks
* High-dose of Intravenous Immune Globulin (IVIG)
o Modifies immune system temporarily
o Provides the body with normal antibodies from donated blood
o Less risk of side effects
o Benefits last 1-2 months and takes a couple weeks to start working

Treatment
* One or more of the treatments may be used to alleviate symptoms caused by Myasthenia Gravis

Resources
Myasthenia Gravis.ppt

Read more...

MYASTHENIA GRAVIS



MYASTHENIA GRAVIS
By Terra Cunningham

DEFINITION
* “A disorder of neuromuscular function thought to be due to the presence of antibodies to acetylcholine receptors at the neuromuscular junction”3

DISCOVERED IN
* First described in 1672 by Thomas Willis and later described in 1890 by German physicians, Samuel Goldflam, Wilhelm Erb, and Friedrich Jolly.

SYMPTOMS
* Drooping of the eyelids
* Double vision
* Difficulty smiling, speaking, swallowing
* Difficulty raising the arms
* Difficulty walking
* Difficulty breathing if chest muscle are affected

CAUSE
* The cause is unknown
* “Antibodies act against the acetylcholine receptor making a nerve come in contact with the muscle. The nerve cell conveys its message to tell the muscle to contract. The antibodies interfere with the message and the muscle contracts less efficiently. Resulting in the weakness of the arms or legs or of the muscles of the head.”4

PREVALENCE
* Today there are an estimated 50,000 cases in the United States
* Myasthenia Gravis can be found in anyone, but it is “most common in females around the third decade of life”1

TREATMENT
* Symptomatic treatment: medications that enhance the function of the acetylcholine system at the neuromuscular junction.
* Medications include – Prostigmin, Mestinon, Mytelase, Tensilon
* Long range treatment is thymectomy.
* Thymectomy is the surgical removal of the thymus gland that lies behind the breastbone and overlies the heart.

Lifestyles
* A person with Myasthenia Gravis can lead a normal life if the medications are taken in the correct dosages and at the right time of the day.

References
* Collier’s Encyclopedia with Bibliography and Index, 1988, volume 17.,Macmillan
* Dictionary of Medical Syndromes, 3rd edition, Magalini
* Dorland's Illustrated Medical Dictionary, 26th edition, 1985, Saunders
* Encyclopedia Americana, 1993, volume 19., Grolier
* The Medical and Health Encyclopedia, volume 1., Southwestern Company

MYASTHENIA GRAVIS.ppt


Read more...

A Potpourri of Neurological Disorders



A Potpourri of Neurological Disorders
By:Stephanie Rodriguez MS RN

Chronic Neurological Problems
Headaches
* Classified based on characteristics of the headache
* Functional vs. Organic type
* May have more than one type of headache
* History & neurologic exam diagnostic keys

Not always chronic…be careful
Pattern
Tension
Migraine
Cluster
Site
Bilateral, basilar, band-like
Unilateral, anterior
Unilateral, occular
Quality
Squeezing, constant
Throbbing
Severe
Pattern
Cycles, years
Periodic, years
Remitting, relapsing
Duration
Days, weeks, months
Hours, days
30-90 min
Onset
Anytime
Prodrome, starts in AM
Nocturnal
Assoc. Sx
Stiff neck
N&V, photo/phono-phobia
Horner syndrome
ONSET: Not reliable or diagnostic

Horner’s Syndrome
HA: Essential History
* Onset this particular headache
* Character of pain, severity and duration
* Associated symptoms
* Prior history, pattern
* Original onset: prior testing, treatment
* Exertional aspects
* Other therapeutic regimens

Physical Exam
* Neurologic examination
* Inspect for local infections, nuchal rigidity
* Palpation for tenderness, bony swellings
* Auscultation for bruits over major arteries

Organic vs. Traumatic vs. Functional: Diagnostics
* CBC: underlying illness, anemia
* Chem panel: if associated vomiting, dehydrated
* U/A
* CT scan: for focal neurological signs, sinuses
* SED rate: if recent onset, > 50 yrs (temporal arteritis)
* No LP for suspected ICP; ↑ association with brain herniation (question from last time: ARTICLE

Don’t Miss It
* Caused by subarachnoid hemorrhage from an aneurysm or head injury
* “Worse headache of my life”
* Changes in LOC, focal neurological signs
* Highly correlated with CVA
* Untreated, 50 % mortality

Headache Teaching Guide
* Keep a calendar/diary
* Avoid triggers
* Medications (purpose, side effects)
o Imitrex: take med at 1st sign of HA, ↓blood flow to brain
* Stress reduction
o Dark quiet room, exercise, relaxation
* Regular exercise
* When to contact PCP

Multiple Sclerosis
Definition
MS is a chronic, progressive, degenerative disorder of the CNS characterized by disseminated demyelination of the nerve fibers of the brain and spinal cord.

Multiple Sclerosis
Etiology
* Cause is unknown.
o Possibly related to viral, immunologic, and genetic factors.
* Susceptibility appears to be inherited with 1st, 2nd, and 3rd degree relatives at slight increased risk.

Pathophysiology
* MS is characterized by chronic inflammation, demyelination, and gliosis in the CNS.
* Autoimmune process is orchestrated by autoreactive T cells (lymphocytes)
* Activated T cells migrate to CNS causing blood-brain barrier disruption.
* Subsequent antigen-antibody reaction within the CNS activates the inflammatory response leading to demyelination of axons, with plaque formation.

A: Normal Nerve Cell
B: Normal Axon
C: Myelin Breakdown
D:Myelin completely disrupted

U-tube: animation
* http://www.youtube.com/watch?v=eE_Y3KMYC0g

Disease Process: Early
* Myelin sheaths of neurons in the brain and spinal cord are initially attacked.
* Myelin sheath is damaged but nerve fiber still intact.
* Nerve impulses are still transmitted but patient may complain of weakness.
* Remission occurs if inflammatory process stops and myelin regenerates.

Disease Process: Late
* If remission does not occur, myelin disruption continues and axon is affected.
* Myelin is replaced by glial scar tissue which forms plaques in the CNS.
* Lacking myelin, nerve impulses slow, axons are destroyed, resulting in permanent loss of function.`

Symptoms
* Initially insidious with symptoms evolving over months to years.
* Systems affected depend on distribution of lesions.
* Disease process may be chronic and progressive or have periods of remission and exacerbation.
* Even in relapsing disease, overall trend is progressive deterioration of neurologic function.

Symptoms: Motor
* Weakness
* Paralysis of limbs, trunk or head.
* Diplopia
* Scanning speech
* Muscle spasticity

Symptoms: Sensory
* Numbness, tingling, parathesia.
* Scotomas (patchy blindness)
* Blurred vision
* Vertigo
* Tinnitus, decreased hearing
* Neuropathic pain
* Radicular pain

Symptoms: Cerebellar
* Nystagmus
* Ataxia
* Dysarthia
* Dysphagia

Symptoms: Emotional
* Emotional stability may be affected
* Depression common co morbidity
* Range of emotions include anger to euphoria.
* Cognitive function usually not affected.
* Emotional lability may negatively affect progress of disease.

Symptoms: Bowel & Bladder
* Symptoms depend on where sclerotic plaque is located.
* Spastic bladder indicates lesion above S2 resulting in small capacity. This yields frequency, urgency, dribbling or incontinence.
* Flaccid bladder results form disruption of reflex arc resulting in loss of sensation or desire to void.
o Crede Method
* Bowel symptoms are usually constipation.

Multiple Sclerosis Drug Therapy
Agent
Corticosteroid (ACTH, Prednisone)
Immunomodulators (B-interferon,Betaseron, Copaxone)
Immunosuppresants (Novantrone)
Cholinergics (Urecholine, Prostigmin)
Anticholinergics (Pro-bathine, Ditropan)
Muscle Relaxants (Valium, baclofen, Zanaflex)

Target Symptom
Exacerbations
Urinary retention; flaccid bladder
Urinary freq. and urgency; spastic bladder
Spasticity

Nursing Care Planning
* Impaired physical mobility
* Self-care deficit
* Impaired skin integrity; risk/actual
* Impaired elimination; urinary, bowel
* Sexual dysfunction
* Interrupted family process

Myasthenia Gravis
Definition & Pathophysiology
* Autoimmune disease of the neuromuscular junction in which antibodies attack acetylcholine (ACh) receptors.
* ACh is prevented from attaching and stimulating muscle contraction
* 90% of patients have ocular manifestations (ocular myasthenia)
* Generalized myasthenia affecting trunk and limbs less common.
* 15% of patients have abnormal thymus glands.
* No other neural disorders accompany MG.
o no sensory loss, reflexes are normal, atrophy is rare.

Myasthenic Crisis
An acute exacerbation of muscle weakness
o triggered by infection, surgery, stress, overdose or or inadequate management of medications
o If muscle weakness affects swallowing and breathing: aspiration, respiratory insufficiency, and infection may result.

Myasthenia Gravis: Symptoms
* Weakness of skeletal muscle
o Muscles are strongest in morning
o Evening: muscle weakness is prominent
* Impaired facial mobility and expression
* Prolonged speech resulting in fading voice
* Possible difficulty in chewing, swallowing
* Proximal muscles of neck, shoulder and hip may be affected
* Course of the disease is variable It most commonly affects young adult women (under 40) and older men (over 60), but it can occur at any age.
* CRISIS: myasthenic crisis is weakness affecting the muscles that control breathing, creating a medical emergency and requiring a respirator for assisted ventilation
Diagnosis
* Diagnosis may be made by H&P.
* Blood tests:
o antibodies to ACh in 90%
* EMG:
o show decreasing response to repeated stimulation of hand muscles
* Tensilon test: shows improved contractility with IV injection of medication.
* NEURO ASSESSMENT: MG expected findings: impairment of eye movements or muscle weakness without any changes in the individual's ability to feel things

Treatment
* Drug therapy – anticholinesterase agents, corticosteroids, immunosuppressants
* Surgical therapy - Thymectomy
* Plasmapheresis
* Intravenous IgG
* Rest!

Huntington’s Disease
* Autosomal dominant genetic disorder
* Deficiency in the acetylcholine and GABA results in excess dopamine.
* Symptoms:
o Clinically opposite of Parkinson’s
o Chorea, intellectual decline, emotional lability
http://www.youtube.com/watch?v=UKbC1jRjs3M
http://www.youtube.com/watch?v=gBtji6Ibbso

Huntington’s Disease: Symptoms
* Abnormal & excessive involuntary movements (chorea)
* Writhing and twisting movements of face, limbs, body.
* Facial involvement affects speech, chewing, swallowing causing aspiration, malnutrition.
* Gait deteriorates with loss of mobility.
* Mental function declines including intellect, emotional lability and psychotic behavior.

Huntington’s Disease Diagnosis
* By symptoms
* By genetic testing as an adult: IMPLICATIONS??
* By prenatal screening

Treatment
* Palliation, symptomatic
* Neuroleptics
* Antidepressants
* Chorea antagonists (Klonopin)
* Fetal tissue transplant (experimental)

Parkinson’s Disease
Definition & Pathophysiology
* Disease of the basal ganglia
* Substantia Nigra:
o Degeneration of dopamine producing neurons
o Disrupts normal balance between dopamine and acetylcholine in the basal ganglia
* Dopamine is essential for normal function of extrapyramidal motor system which controls
o posture
o support
o voluntary motion

Dopaminergic Synaptic Activity
Good to know: These neurotransmitters and functions highly related to “reward” and to psych drug actions
Symptoms
* Onset:
o gradual, insidious, and prolonged
* Classic triad:
o tremor, rigidity and bradykinesia
* Initially:
o may involve one side of the body with mild tremor, slight limp and decreased arm swing
* With progression:
o classic shuffling and propulsive gait with flexed arms and loss of postural reflexes develops
o Slowed reflexes include decrease blinking, drooling, and masked facies

Parkinson’s Presentation

Parkinson’s Disease

A firm diagnosis of Parkinson’s is made only if at least two of the classic triad symptoms are present.

Diagnosis Confirmed: improvement of symptoms once anti-parkinsonian drugs initiated

Parkinson’s Disease: Treatment

Drug
* Dopaminergic (levodopa, sinemet, parlodel, etc.)
* Anticholinergic (artane, cogentin, symmetrel, etc.)
* Antihistamine * MAO inhibitor
* COMT inhibitor’s (comtan, tasmar)

Symptom relieved
* Bradykinesia, tremor, rigidity
* Tremor
* Tremor, rigidity
* Bradykinesia, tremor, rigidity
* Slows breakdown of levodopa

Parkinson’s Disease: Treatment Surgical
* Ablation
* Deep brain stimulation
* Fetal tissue transplant

Nutritional
* Hi fiber
* Mechanical soft
* Frequent small meals
* Lo-protein in HS

Nursing Care Planning
* Impaired physical mobility
o Teaching necessary
* Dressing/grooming self-care deficit
* Impaired skin integrity-risk/actual
* Impaired urinary elimination
* Sexual dysfunction
* Interrupted family process

Seizure Disorders & Epilepsy
Definitions
Seizure:
o paroxysmal, uncontrolled electrical discharge of neurons in the brain that interrupts normal function
Epilepsy:
o spontaneously recurring seizures caused by a chronic underlying condition

Question:
* The population with the highest prevalence of new-onset epilepsy is:

A: over the age of 60
B: children under 5
C: adolescents between 12-18 yrs
D: middle-aged men

Seizure Classification
http://www.youtube.com/watch?v=CDccChHrgRA

Seizure Disorders & Epilepsy: Classifying Seizures
Two major classes:
* Generalized
* Partial

Depending on type, phases may include:
* Prodromal phase- signs & activity preceeding seizure
* Aural phase- sensory warning
* Ictal phase- full seizure
* Postictal phase- recovery

Seizure Disorders & Epilepsy: Generalized
* Absence
* Myoclonic
* Clonic
* Tonic
* Tonic-Clonic
* Atonic

Seizure Disorders & Epilepsy: Partial Seizures
* Simple: no impairment of consciousness
o Symptoms: motor, somatosensory, autonomic, psychic
* Complex: impairment of consciousness
o Simple with progression to LOC/impairment
+ Symptoms: no other features, simple partial seizure features, automatisms
o Impairment of consciousness at onset
+ Symptoms: no other features, simple partial seizure features, automatisms

Seizure Disorders & Epilepsy: Status Epilepticus
* Medical emergency
* Seizure repeated continuously
o Tonic clonic: hypoxia could develop if muscle contraction is lengthened. Also: hypoglycemia, acidosis, hypothermia, brain damage, death
+ IV administration of antiepileptics
+ Maintain airway patency

Seizure Disorders & Epilepsy: Diagnostic Studies
* Most useful tool:
o a reliable and accurate description of the event, and the patient’s health history
* PE
* Electroencephalography (EEG):
o only useful when it shows abnormalities
* Labs:
o CBC, U/A, BMP
* PET scan, CT, MRI, MRA, MRS

Drug Therapy
* Can be helpful in preventing ongoing seizures following a head injury and should be first priority to decrease likelihood of second seizure

Seizure Disorders & Epilepsy Drug Therapy for Tonic-Clonic and Partial Seizures
* Carbamezepine/ Tegretol
* Divalproex/ Depakote
* Gabapentin/ Neurontin
* Lamotrigine/ Lamictal
* Levetiracetam/ Keppra
* Phenytoin/ Dilantin
* Tiagabine/ Gabitril
* Topiramate/ Topamax
* Valproic Acid/ Depakene
* Felbamate/ Felbatol *
* Phenobarbitol**

*Felbatol has been associated with aplastic anemia
**Phenobarbitol is a barbituate
Seizure Disorders & Epilepsy
Drug Therapy for:
Absence, Akinetic, & Myoclonic Seizure
* Clonazepam/ Klonopin
* Divalproex/ Depakote
* Valproic Acid/ Depakene
* Ethosuximide/ Zarontin
* Phenobarbitol

Seizure Disorders & Epilepsy Toxic Side Effects
* Diplopia
* Drowsiness
* Ataxia
* Mental slowing
assess for dose related toxicity including nystagmus, hand and gait coordination, cognitive function, general alertness
Seizure Disorders & Epilepsy
Idiopathic Side Effects
* Skin rash
* Gingival hyperplasia (dilantin)
* Bone marrow & blood dyscrasia
* Abnormal liver function
* Abnormal kidney function

Seizure Disorders & Epilepsy: Nursing Care

* Assure oxygen and suction equipment at bedside
o http://www.youtube.com/watch?v=H2vH1igOoh0
* Safety precautions in active stage
o Support/ protect head
o Turn to side
o Lossen constricted clothing
o Ease to floor
* Time seizure, record details of seizure and post-ictal phase
* Patient teaching:
o importance of good seizure control using medication as ordered
o Medical alert bracelet
o Avoid decreased sleep, increased EtOH, fatigue
o Regular meals/ snacks

A Potpourri of Neurological Disorders.ppt

Read more...

Myasthenia Gravis



Myasthenia Gravis

Chronic autoimmune disease of the neuromotor junction presents as muscle weakness and fatigue

Clinical manifestations
* Weakness
* Fatigue
* Ptosis
* Diplopia
* Facial muscles weakness
* Dysphagia
* Nasal quality to speech
* Respiratory distress
* Muscles involved – eyes, eyelids, chewing, swallowing
* Speech affected
* Muscles of the trunk and limbs less affected
* Proximal muscles of the neck, shoulder and hips are affected
* No sensory loss
* Reflexes normal
* Muscle atrophy rare
* Pt may have exacerbation and remission

Exacerbation of MG
* Emotional stress
* Pregnancy
* Menses
* Secondary illness
* Trauma
* Temperature extremes
* Hypokalemia
* Drugs – aminoglycosides antibiotics, beta blockers, procainamide, quinidine, phentoin, and some psychotropic drugs

Diagnostic
* History and physical
* Antibodies to ACH receptors
* Upward gaze
* EMG
* Tensilon test

Management
* Anticholinesterase drugs – mestinon, prostigmin
* Corticosteriods
* Immunosuppressant drugs – imuran, cytoxan
* Must check for other drug interactions antibiotic, antiarrhythmics, diuretics etc.
* Surgery – removal of thymus gland
* plasmapheresis

Nursing care
* Admin. anticholinesterase drugs
* Respiratory assessment – suction
* Elevate HOB when eating
* Check swallow reflex – oral motor strength
* Plan activities – muscles strongest in morning
* Assess muscle strength before and after activity

Myasthenic crisis
* Due to exacerbation of myasthenia or failure to take drug
* S/S – improved strength with anticholinesterase drugs, inc. weakness of skeletal muscles, ptosis, difficulty on swallowing, articulating words, dyspnea

Cholinergic crisis
* Due to overdose
* S/S – weakness within 1 hour of taking anticholinesterase drug, ptosis, dyspnea, blurred vision, salivations, diarrhea, N/V, abd. cramps, inc. bronchial secretions, sweating, lacrimation
* Due to overdose
* S/S – weakness within 1 hour of taking anticholinesterase drug, ptosis, dyspnea, blurred vision, salivations, diarrhea, N/V, abd. cramps, inc. bronchial secretions, sweating, lacrimation, difficulty swallowing, dyspnea

Nursing DX
Discharge teaching
* Instruct on disease process
* Importance of drug regime – sch drugs at peak action at mealtime, other drug interactions
* Suction equipment at home
* S/S of underdose and overdose of meds
* Instruct on precipitating factors
* Diet – semisolid food
* Rest, Plan activities
* Use of adaptive devices – OT, home care
* MG support group, Community resources

Amyotrophic Lateral Sclerosis
* Known as Lou Gehrig’s disease
* Cause unknown
* Motor neurons in the brainstem and spinal cord gradually degenerate
* Electrical and chemical messages originating in the brain do not reach the muscles to activate them
* Death within 2-6 years after diagnosis

ALS
* S/S – weakness of upper extremities
* Dysarthria
* Dysphagia
* Weakness may begin in legs
* Muscle wasting, fasciculations
* Sensory intact
* Death usually results from respiratory infection

Dx
* Difficult to dx- rule out other diseases
* EMG
* MRI
ALS
* Treatment – Riluzole to slow progression
* No cure
* Cognition is intact

Management
* Supportive therapy – OT, PT, RT
* Assess client’s ability to do ADL
* Conserve energy
* Encourage small freq meals
* Suction equipment
* Soft collar to stabilize head
* Adaptive equipment
* Allow time to complete activities
* Avoid exposure to anyone with respiratory infection
* Good posture and swallowing techniques
* Diaphragmatic breathing
* Follow up pulmonary tests
* Home care
* ALS support group

Multiple Sclerosis
* A chronic progressive degenerative disease that affects the myelin sheath of neurons in the CNS
* Cause unknown – genetic, virus, autoimmune response, inherited, antigen-antibody reaction

Clinical Course
* Relapsing – remitting: relapses with full recovery and residual deficit with recovery
* Primary – progressive: dx progression from onset with occ plateaus and temp. minor improvements
* Secondary – progressive: relapsing-remitting course followed by progression with or without relapses, minor remission and plateaus
* Progressive – relapsing: Progressive dx, with acute relapses with or without full recovery, periods between relapses cont. progression

Dx
* History and Physical
* CSF analysis
* CT scan
* MRI

Clinical manifestations
* S/S may vary
* Motor- weakness or paralysis,of the limbs, trunk, or head, speech problems, spasticity of the muscles
* Sensory – numbness, tingling, paresthesia, visual changes, vertigo, tinnitus, decrease hearing, chronic neuropathic pain, radicular pain (pain in thoracic area and abdominal region), lhermitte’s phenomenon – electric shock radiating down the spine, into the limbs with the flexion of the neck

Clinical manifestations
* Cerebellar signs – nystagmus, ataxia, dysarthria, dysphagia
* B/B function can be affected
* Constipation a problem
* Spastic bladder – incont.
* Flaccid bladder – no sensation of voiding
* Mood swings, Intellect intact
* S/S may be triggered by physical, emotional trauma, fatigue and infection

Medical Management
* Corticosteriods
* Immunomodulators – B-interferon
* Immunosuppressants
* Cholinergics - flaccid bladder
* Anticholinergic – spastic bladder
* Muscle relaxants
* Surgery – control tremors

Nursing Dx
Guillain Barre
* An acute form of polyneuritis
* Etiology unknown
* A cell mediated immunologic reaction directed at the peripheral nerves
* Involves degeneration of the myelin sheath of the peripheral nerves
* In half of cases, an upper respiratory or GI infection precedes the onset of the syndrome by 1-4 weeks
* Antecedent illness-cytomegalovirus, Epstein Barr virus, mycoplasma pneumonia, salmonella typhosa, campylobacter jejuni, HIV
* A chronic form of GB paralysis evolves more slowly with no involvement of respiratory of cranial nerves
* With support, pt will recover

DX
* History and physical exam
* Electrophysiological studies
* Cerebrospinal fluid with elevated protein levels
* EMG

Characteristics of GB
* Ascending weakness usually beginning in the lower extremities and spreading to trunk, upper extremities and face
* Improvement and recovery occur with remyelination; if nerve axons are damaged
* Some residual deficit may remain
* Recovery is usually 6 months with 85%-90% of clients recovering completely
* 10% have recurrence and 20% have long term disabilities/emotional trauma

Guillian Barre
* Complication- is respiratory failure
* Impt to monitor respiratory rate, depth, vital capacity
* Client may be intubated with mechanical ventilation
* Complications can occur due to immobility

Clinical Manifestations
* Flaccid quadraplegia
* Facial weakness, dysphagia, diplopia, hypotonia
* Autonomic dysfunction found in severe muscle involvement and respiratory muscle paralysis – orthostatic hypotension, hypertension, pupillary disturbances, sweating dysfunction, bradycardia, paralytic ileus, urinary retention
* Weakness
* Paresthesia of the limbs
* Loss of deep tendon reflexes
* Deep, aching muscle pain in shoulder and thighs
* Respiratory compromise or failure-dyspnea, dec. breath sounds, dec. tidal volume (air in & out)

Medical/Nursing Management
* Supportive care
* Immunoglobulin therapy
* Pain control worse at night due to paresthesia, muscle aches and cramps
* Problems - airway, aspiration, communication problems, orthostatic hypotension, nutritional intake
* Plasmaphoresis
* ABGs
* Assist ability to perform self care
* Set communication system
* Work closely with PT, OT
* Monitor for complications of immobility
* Safety measures provided

Myasthenia Gravis.ppt

Read more...
All links posted here are collected from various websites. No video or powerpoint files are uploaded on this blog. If you are the original author and do not wish to display your content on this blog please Email me anandkumarreddy at gmail dot com I will remove it. The contents of this blog are meant for educational purpose and not for commercial use. If you use any content give due credit to the original author.

This site uses cookies from Google to deliver its services, to personalise ads and to analyse traffic. Information about your use of this site is shared with Google. By using this site, you agree to its use of cookies.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP